Efficacy and Tolerability of Peginterferon α-2a and Peginterferon α-2b, Both plus Ribavirin, for Chronic Hepatitis C: A Meta-Analysis of Randomized Controlled Trials

Zongguo Yang, Liping Zhuang, Lei Yang, and Xiaorong Chen

1 Shanghai Public Health Clinical Center Affiliated to Fudan University, Department of Traditional Chinese Medicine, No. 2901 Caolang Road, Jinshan District, Shanghai 201508, China
2 Shanghai Medical College, Fudan University, Department of Oncology, Shanghai 200032, China
3 Shanghai Cancer Center, Department of Integrative Medicine, Shanghai 200032, China
4 The Central Hospital of China Aerospace Corporation, Beijing 100049, China

Correspondence should be addressed to Xiaorong Chen; xiaorong3chen@yahoo.com.cn

Received 29 December 2012; Revised 26 February 2013; Accepted 17 March 2013

1. Introduction

The World Health Organization has estimated that up to 170 million people (approximately 3% of the world population) worldwide might be infected with hepatitis C virus (HCV). This virus is responsible for approximately 350,000 deaths every year. HCV is cleared spontaneously in only approximately 20% of individuals. Chronic infection frequently progresses to cirrhosis, end-stage liver disease, hepatocellular carcinoma, and death [1–4].

Currently, in many countries, the recommended therapy for chronic hepatitis C (CHC) is still the combination of peginterferon α and ribavirin [1, 2]. Two licensed products of peginterferon α are available: peginterferon α-2a (Pegasys, Hoffmann-La Roche, Nutley, NJ, USA) and peginterferon α-2b (Peg-Intron, Schering Plough Corp., Kenilworth, NJ, USA). However, differences in structural modifications and dosing (weight-adjusted versus fixed) between the two peginterferons may lead to various clinical outcomes. In addition, a recommendation about the two regimens has not been proposed in the current guidelines [5–11]. Although recent studies have compared the response rates obtained using the two peginterferons in CHC, they have failed to reach a consensus as to which treatment options are the most effective.

Some systematic reviews [12–15], which include meeting abstracts or HCV/HIV coinfected patients, concluded that peginterferon α-2a has higher sustained virologic response (SVR) than peginterferon α-2b in CHC but revealed that...
both have similar safety. The virologic responses and tolerability of peginterferon plus ribavirin in HCV/HIV coinfected patients are substantially different from those in chronic HCV monoinfected patient. In addition, some reported meeting abstracts were found to be inadequate. Thus, we performed a meta-analysis of randomized controlled trials (RCTs) with critical inclusion and exclusion criteria to evaluate the efficacy and tolerability of the two regimens.

2. Materials and Methods

2.1. Search Strategy. We searched PubMed, Ovid, and Cochrane libraries until August 30, 2012. The following medical subject headings were used: “Hepatitis C, Chronic,” “interferons,” “peginterferon alfa/alpha/α-2a,” “peginterferon alfa/alpha/α-2b,” and “ribavirin.” Electronic searches were supplemented with manual searches of reference lists of all retrieved review articles, primary studies, and abstracts from meetings to identify other studies not found in the electronic searches. The literature was searched by two authors (Z. Yang and L. Zhuang) independently.

2.2. Study Selection. Two authors independently selected trials and discussed them with each other when inconsistencies were found. Articles that meet the following criteria were included: (1) study types, randomized controlled trials; (2) participants, chronic HCV virus monoinfection patients either naive or retreatment were randomly divided into two groups; (3) interventions, peginterferon α-2a and peginterferon α-2b, both plus ribavirin; (4) outcome measures, studies that used one or more of the following measurements were eligible: rapid virologic response (RVR), early virologic response (EVR), end-of-treatment virologic response (ETR), SVR, relapse rate, and discontinuation rate; and (5) full texts available.

Studies with the following situations were excluded: (1) followup period less than 6 months and (2) studies that included patients with other liver diseases (e.g., HBV infection, human immunodeficiency virus infection, and hepatocellular carcinoma) aside from HCV.

2.3. Quality Assessment. The methodological qualities of the included RCTs were assessed according to Cochrane Collaboration’s tool described in Handbook version 5.1.0 [16]. Two authors (Z. G. Yang and L. Yang) assessed the quality independently, and inconsistency was discussed with a third review author (X. R. Chen) who acted as an arbiter.

2.4. Data Extraction. Two researchers read the full texts independently and extracted the following contents: publication data (first author’s name, year of publication, and country of population studied), study design, sample size, patient characteristics (age, gender, body weight, distribution of genotype, and liver histology), treatment protocol (peginterferon type and dose, ribavirin dose), outcome measures (RVR, EVR, ETR, SVR, relapse rate, and discontinuation rate), and reasons for discontinuing combination therapy. Authors were contacted by e-mail for additional information if data were unavailable.

2.5. Definitions. Chronic hepatitis C is defined by anti-HCV positive, HCV RNA positive as determined by a qualitative polymerase chain reaction (PCR) assay for more than 6 months. The primary outcome measure of efficacy of SVR was defined by a sensitive PCR assay as the absence of HCV RNA from serum at 24 weeks after completion of therapy. Secondary outcome measures of tolerability, including discontinuation rate, RVR, EVR, and ETR, were also determined. RVR was defined using a sensitive PCR assay as undetectable HCV RNA at 4 weeks after treatment. EVR was defined as ≥2 log reduction or complete absence of HCV RNA at 12 weeks after therapy compared with the baseline level. Undetectable virus at the end of either a 24-week or 48-week course of therapy was referred to as ETR. Virologic relapse refers to the reappearance of HCV RNA in serum after treatment was discontinued and ETR was documented.

2.6. Statistical Methods. Data were processed in accordance with the Cochrane Handbook [16]. Intervention effects were expressed with odds ratios (ORs) and associated 95% confidence intervals (CIs) for dichotomous data. By contrast, the effects were expressed with mean differences and 95% CIs for continuous data. Heterogeneity among studies was informally assessed by visual inspection of forest plots and formally estimated using $\chi^2$ and $I^2$ tests (both $P > 0.05$; $I^2 < 50\%$ indicates no evidence of heterogeneity between the pooled studies) [17]. The fixed-effects model was first used for meta-analyses. The random-effects model was used in the presence of heterogeneity. Description analysis was performed when the quantitative data could not be pooled. Intention-to-treat (ITT) principle was used. Review Manage (v. 5.1; The Cochrane Collaboration) was used for data analysis.

3. Results

3.1. Study and Patient Characteristics. A total of 1166 abstracts of clinical trials were found and reviewed. Of these 1166 abstracts, 45 were retrieved, 6 [18–23] were excluded because they were published as abstract proceedings, 1 [24] was excluded because patients received monotherapy of peginterferon α-2a/2b at the first 4 weeks, 1 [25] was excluded because it was not designed randomly, 1 [26] was excluded because patients received 1.0 μg/kg peginterferon α-2b, 1 [27] was excluded because it included patients with HCV/HIV coinfection, and 1 [28] was excluded because duplicate data from the same medical center were published. Finally, 7 trials [5–11] met our inclusion criteria (Table 1).

Totally 1845 and 1823 patients were randomly treated with peginterferon α-2a and peginterferon α-2b, respectively, both plus ribavirin. The baseline characteristics of each study included in this meta-analysis are described in Table 2.

3.2. Methodological Quality Assessment. All studies included in this meta-analysis were described as randomized. Three
Table 1: Baseline characteristics of the included trials in this meta-analysis.

| Study               | Peginterferon group | Baseline treatment history | HCV genotype | Treatment in weeks | Country     | Publication year | Study type |
|---------------------|---------------------|---------------------------|--------------|-------------------|-------------|------------------|------------|
| Yenice et al. [5]   | α-2a 180μg/week; α-2b 1.5μg/kg/week | Naïve | 1 | 24 or 48 | Turkey | 2006 | RCT |
| Di Bisceglie et al. [6] | α-2a 180μg/week; α-2b 1.5μg/kg/week | Naïve | 1 | 12 | USA | 2007 | RCT |
| Scotto et al. [7]   | α-2a 180μg/week; α-2b 1.5μg/kg/week | Nonresponders | 1,2,3,4 | 48 | Italy | 2008 | RCT |
| McHutchison et al. [8] | α-2a 180μg/week; α-2b 1.5μg/kg/week | Naïve | 1 | 24 or 48 | IDEAL study team | 2009 | RCT |
| Rumi et al. [9]     | α-2a 180μg/week; α-2b 1.5μg/kg/week | Naïve | 1,2,3,4 | 24 or 48 | Italy | 2010 | RCT |
| Ascione et al. [10] | α-2a 180μg/week; α-2b 1.5μg/kg/week | Naïve | 1b | 48 | Italy | 2010 | RCT |
| Mach et al. [11]    | α-2a 180μg/week; α-2b 1.5μg/kg/week | Naïve | 1b | 48 | Poland | 2011 | RCT |

Table 2: Baseline characteristics in the two groups of peginterferon α-2a and peginterferon α-2b in this meta-analysis.

| Study               | Peginterferon group | Total patients | Mean age (years) | Gender (male/female) | HCV genotype (1/2/3/4) | F3-4 OR cirrhosis, N (%) | Body weight (kg) | BMI (kg/m²) |
|---------------------|---------------------|----------------|------------------|----------------------|------------------------|-------------------------|------------------|-------------|
| Yenice et al. [5]   | α-2a | 37 | 49.95 | 13/24 | 37/0/0/0 | NA | NA | NA |
| Di Bisceglie et al. [6] | α-2a | 189 | 46.9 ± 0.52 | 121/68 | 189/0/0/0 | 28 (14.8) | 86.5 ± 1.34 | 29.2 ± 0.44 |
| Scotto et al. [7]   | α-2a | 71 | 45.86 ± 9.33 | 42/29 | 45/6/8/12 | 13 (18.3) | 80.7 | 18.5–24.9 (n = 32), 25–29.9 (n = 34), ≥30 (n = 5) |
| McHutchison et al. [8] | α-2a | 1035 | 47.6 ± 8.2 | 613/422 | 1035/0/0/0 | 110 (10.6) | 82.8 ± 16.6 | NA |
| Rumi et al. [9]     | α-2a | 212 | 51.6 ± 12.0 | 128/84 | 91/69/34/18 | 43 (20.3) | 72.2 ± 14.6 | 25.5 ± 4.4 |
| Ascione et al. [10] | α-2a | 160 | 51.3 ± 10.3 | 81/79 | 89/49/18/4 | 33 (20.6) | 70.4 ± 10.6 | 25.3 ± 3.1 |
| Mach et al. [11]    | α-2a | 138 | 45.2 ± 10.5 | 80/58 | 138/0/0/0 | 13 (9.4) | 24.5 ± 0.9 | NA |

NA: not available; BMI: Body mass index; † Ishak score S5, 6.
F0–4 (F0: no fibrosis; F1: portal fibrosis without septa; F2: portal fibrosis with few septa; F3: numerous septa without cirrhosis; F4: cirrhosis).
All baseline characteristics were comparative between the two groups.

Studies [5, 6, 11] did not report the method of randomization, but randomization was adequate in other studies [7–10]. Among these studies, two were randomized by a computer-generated randomization list [9, 10], one was randomized by an interactive voice system [8], and the study by Scotto et al. was randomized by a table of random numbers [7]. One study revealed that the randomization list was not available to the treating physicians. Double blinding was described in one trial by McHutchison et al. [8]. And, Ascione et al. [10] designed a study where the physician received the report on the allocation of each patient from an independent researcher who knew nothing about the patient except for the genotype. The statistical analyses in one study by Yenice et al. [5] were not based on ITT, and more than 20% of the participants in the study by McHutchison et al. were lost to followup, both of which were considered as high risk in the item of...
incomplete outcome data. No descriptions of lost to followup were found in the two studies by Di Bisceglie et al. [6] and Scotto et al. [7], thus accounting for the ambiguity in the item of incomplete outcome. No patient was lost to followup in the study by Ascione et al., and the other studies described the lost to followup participants, which were balanced between the two groups and considered low risk. Selective reporting was found in the study by Di Bisceglie et al. because it failed to include the expected results (e.g., SVR rate) for such a study. The other potential biases were unclear in these trials (Figure 1).

3.3. Virologic Responses. The overall SVR rates for CHC patients treated with peginterferon α-2a plus ribavirin and CHC patients treated with peginterferon α-2b plus ribavirin were 46.7% (773/1656), and 42.4% (692/1632), respectively (OR = 1.20, 95% CI = 1.04–1.38, and P = 0.01; Figure 2(a)). For naïve patients with no interferon experience, subgroup analysis found that the SVR rate was significantly higher in the peginterferon α-2a group than in the peginterferon α-2b group (47.9% versus 43.5%, OR = 1.20, 95% CI = 1.04–1.39, P = 0.01, Figure 2(b)). For genotype 1/4 patients, peginterferon α-2a could obtain a higher SVR than peginterferon α-2b (42.2% versus 38.3%, OR = 1.17, 95% CI = 1.01–1.36, P = 0.03, Figure 2(c)). For CHC patients with genotype 2/3, peginterferon α-2a might achieve a higher SVR rate than peginterferon α-2b (82.6% versus 74.3%, OR = 1.71, 95% CI = 1.01–2.89, and P = 0.01; Figure 2(d)).

Only three studies [6, 8, 9] reported the RVR rate in patients who received peginterferons plus ribavirin. No difference in RVR rate was found between the two regimens (23.2% versus 23.4%, OR = 1.01, 95% CI = 0.83–1.23, and P = 0.91; Figure 3(a)). However, patients treated with peginterferon α-2a could achieve significantly higher EVR rates than those treated with peginterferon α-2b (56.1% versus 49.8%, OR = 1.32, 95% CI = 1.04–1.27, and P = 0.32; Figure 3(b)).

Meta-analysis of RCTs [5, 7–11] by a fixed-effects model (P = 0.17, I^2 = 36%) revealed that, compared with peginterferon α-2b, peginterferon α-2a increased the ETR rate significantly in patients with chronic hepatitis C (67.9% versus 56.6%, OR = 1.66, 95% CI = 1.43–1.92, and P < 0.0001; Figure 3(c)).

3.4. Discontinuation Rate and Dose Modification. All the patients that did not complete the treatment duration were considered as discontinuing therapy, either for adverse events or nonsafety reasons. Of the studies included in this meta-analysis, two [6, 7] reported the number of patients who withdrew from treatment for nonsafety reasons, whereas one
| Study or subgroup | Peginterferon α-2a Events | Peginterferon α-2b Events | Weight | Odds ratio M-H, fixed, 95% CI | Odds ratio M-H, fixed, 95% CI |
|------------------|--------------------------|--------------------------|--------|-------------------------------|-------------------------------|
| Yenice et al., 2006 | 18                       | 40                       | 13     | 40                           | 2%                           |
| Scotto et al., 2008  | 14                       | 71                       | 13     | 72                           | 2.9%                         |
| McHutchison et al., 2009 | 423                      | 1035                     | 406    | 1019                          | 68.1%                        |
| Rumi et al., 2010    | 140                      | 212                      | 119    | 219                          | 11.2%                        |
| Ascione et al., 2010 | 110                      | 160                      | 87     | 160                          | 7.6%                         |
| Mach et al., 2011    | 68                       | 138                      | 54     | 122                          | 8.2%                         |
| **Total (95% CI)**  | **1656**                 | **1632**                 | **100%**| **1.2 [1.04, 1.39]**         |                               |
| Total events        | 773                      | 692                      |        |                               |                               |
| Heterogeneity: $\chi^2 = 8.84$, df = 5 ($P = 0.12$); $I^2 = 43\%$ | | | | | |
| Test for overall effect: $Z = 2.56$ ($P = 0.01$) | | | | | |

(a) The overall SVR rate of CHC patients treated with the two types of peginterferons

| Study or subgroup | Peginterferon α-2a Events | Peginterferon α-2b Events | Weight | Odds ratio M-H, fixed, 95% CI | Odds ratio M-H, fixed, 95% CI |
|------------------|--------------------------|--------------------------|--------|-------------------------------|-------------------------------|
| Yenice et al., 2006 | 18                       | 40                       | 13     | 40                           | 2.1%                         |
| McHutchison et al., 2009 | 423                      | 1035                     | 406    | 1019                          | 70.1%                        |
| Rumi et al., 2010    | 140                      | 212                      | 119    | 219                          | 11.5%                        |
| Ascione et al., 2010 | 110                      | 160                      | 87     | 160                          | 7.9%                         |
| Mach et al., 2011    | 68                       | 138                      | 54     | 122                          | 8.4%                         |
| **Total (95% CI)**  | **1585**                 | **1560**                 | **100%**| **1.2 [1.04, 1.39]**         |                               |
| Total events        | 759                      | 679                      |        |                               |                               |
| Heterogeneity: $\chi^2 = 8.81$, df = 4 ($P = 0.07$); $I^2 = 55\%$ | | | | | |
| Test for overall effect: $Z = 2.55$ ($P = 0.01$) | | | | | |

(b) The SVR rate of naïve CHC patients

| Study or subgroup | Peginterferon α-2a Events | Peginterferon α-2b Events | Weight | Odds ratio M-H, fixed, 95% CI | Odds ratio M-H, fixed, 95% CI |
|------------------|--------------------------|--------------------------|--------|-------------------------------|-------------------------------|
| Yenice et al., 2006 | 18                       | 40                       | 13     | 40                           | 2.2%                         |
| Scotto et al., 2008  | 9                        | 57                       | 7      | 58                           | 1.8%                         |
| McHutchison et al., 2009 | 423                      | 1035                     | 406    | 1019                          | 75.8%                        |
| Rumi et al., 2010    | 52                       | 109                      | 36     | 113                          | 5.8%                         |
| Ascione et al., 2010 | 51                       | 93                       | 37     | 93                           | 5.2%                         |
| Mach et al., 2011    | 68                       | 138                      | 54     | 122                          | 9.1%                         |
| **Total (95% CI)**  | **1472**                 | **1445**                 | **100%**| **1.17 [1.01, 1.36]**        |                               |
| Total events        | 621                      | 553                      |        |                               |                               |
| Heterogeneity: $\chi^2 = 8.06$, df = 5 ($P = 0.15$); $I^2 = 38\%$ | | | | | |
| Test for overall effect: $Z = 2.12$ ($P = 0.03$) | | | | | |

(c) The SVR rate of CHC patients with HCV genotype 1 or 4

| Study or subgroup | Peginterferon α-2a Events | Peginterferon α-2b Events | Weight | Odds ratio M-H, fixed, 95% CI | Odds ratio M-H, fixed, 95% CI |
|------------------|--------------------------|--------------------------|--------|-------------------------------|-------------------------------|
| Scotto et al., 2008  | 5                        | 14                       | 6      | 14                           | 17.7%                        |
| Rumi et al., 2010    | 88                       | 103                      | 83     | 106                          | 54.8%                        |
| Ascione et al., 2010 | 59                       | 67                       | 50     | 67                           | 27.5%                        |
| **Total (95% CI)**  | **184**                  | **187**                  | **100%**| **1.71 [1.01, 2.89]**        |                               |
| Total events        | 152                      | 139                      |        |                               |                               |
| Heterogeneity: $\chi^2 = 1.84$, df = 2 ($P = 0.4$); $I^2 = 0\%$ | | | | | |
| Test for overall effect: $Z = 2.01$ ($P = 0.04$) | | | | | |

(d) The SVR rate of CHC patients with HCV genotype 2 or 3

Figure 2: SVR rates of chronic hepatitis C patients who received the two regimens of peginterferon α-2a and peginterferon α-2b, both plus ribavirin.
(with any HCV genotype ($P = 0.11$), $95\% \text{CI} = 0.61$–$0.84$, and $P < 0.0001$ meta-analysis of RCTs [5, 6, 8–10] by a fixed-effects model ($\alpha = 0.09$, $I^2 = 25\%$) revealed no difference in the two types of peginterferons ($22.2\%$ versus $20.7\%$, OR = 1.09, $95\% \text{CI} = 0.90$–$1.31$, and $P = 0.26$; Figure 4(a)). By contrast, meta-analysis of RCTs [5, 6, 8–10] by a fixed-effects model ($P = 0.09$, $I^2 = 50\%$) revealed that peginterferon $\alpha$-2a had a significantly lower discontinuation rate than peginterferon $\alpha$-2b for naive HCV patients ($27.9\%$ versus $33.9\%$, OR = 0.71, $95\% \text{CI} = 0.61$–$0.84$, and $P < 0.0001$; Figure 4(b)).

No adequate data of peginterferon $\alpha$ or ribavirin dose reduction were reported in the studies by Yenice et al. [5], Di Bisceglie et al. [6], Ascione et al. [10], and Mach et al. [11]. However, the same dose reduction was applied for both arms in two studies [6, 10]. For the modification of peginterferon dose, meta-analysis of RCTs [7–9] by a fixed-effects model ($P = 0.26$, $I^2 = 25\%$) indicated no difference in the two types of peginterferons ($22.2\%$ versus $20.7\%$, OR = 1.09, $95\% \text{CI} = 0.90$–$1.31$, and $P = 0.40$; Figure 4(c)). For the reduction of ribavirin dose, meta-analysis of RCTs [5, 7–9] by a fixed-effects model ($P = 0.76$, $I^2 = 0\%$) revealed no statistical

---

### Table: Discontinuation rates for CHC patients, including naive and retreatment ones

| Study or subgroup | Peginterferon $\alpha$-2a | Peginterferon $\alpha$-2b |
|------------------|---------------------------|---------------------------|
| Di Bisceglie et al., 2007 | 79 | 94 |
| Ascione et al., 2010 | 123 | 1019 |
| Rumi et al., 2010 | 132 | 219 |

Total (95% CI) 1429 100% 1.01 [0.83, 1.23]

Test for overall effect: $Z = 0.11$ ($P = 0.91$)

---

### Table: EVR rate comparison

| Study or subgroup | Peginterferon $\alpha$-2a | Peginterferon $\alpha$-2b |
|------------------|---------------------------|---------------------------|
| Yenice et al., 2006 | 28 | 27 |
| Ascione et al., 2010 | 134 | 103 |
| Mach et al., 2011 | 113 | 87 |

Total (95% CI) 1632 100% 1.66 [1.43, 1.92]

Test for overall effect: $Z = 6.78$ ($P < 0.00001$)

---

### Table: ETR rate comparison

| Study or subgroup | Peginterferon $\alpha$-2a | Peginterferon $\alpha$-2b |
|------------------|---------------------------|---------------------------|
| Yenice et al., 2006 | 28 | 27 |
| Ascione et al., 2010 | 134 | 103 |
| Mach et al., 2011 | 113 | 87 |

Total (95% CI) 1656 100% 1.66 [1.43, 1.92]

Test for overall effect: $Z = 6.78$ ($P < 0.00001$)

---

**Figure 3:** The RVR, EVR, and ETR rates of CHC patients treated with the two regimens.
| Study or subgroup | Peginterferon α-2a | Peginterferon α-2b | Weight | Odds ratio M-H, random, 95% CI | Odds ratio M-H, random, 95% CI |
|------------------|-------------------|-------------------|--------|-------------------------------|-------------------------------|
| Yenice et al., 2006 | 3 | 40 | 3 | 40 | 5.1% | 1 [0.19, 5.28] |
| Di Bisceglie et al., 2007 | 18 | 189 | 27 | 191 | 19% | 0.64 [0.34, 1.2] |
| Scotto et al., 2008 | 17 | 71 | 12 | 72 | 14.3% | 1.57 [0.69, 3.59] |
| McHutchison et al., 2009 | 414 | 1035 | 479 | 1019 | 33.1% | 0.75 [0.63, 0.9] |
| Ascione et al., 2010 | 18 | 212 | 23 | 224 | 18.6% | 0.81 [0.42, 1.55] |
| Rumi et al., 2010 | 4 | 160 | 22 | 160 | 9.9% | 0.16 [0.05, 0.48] |
| **Total (95% CI)** | **1707** | **1706** | **100%** | **0.72 [0.48, 1.07]** |  |

Total events 474 566

Heterogeneity: $\chi^2 = 0.12, df = 5 (P = 0.05); I^2 = 55$

Test for overall effect: $Z = 1.62 (P = 0.11)$

- **(a) The overall discontinuation rate**

| Study or subgroup | Peginterferon α-2a | Peginterferon α-2b | Weight | Odds ratio M-H, fixed, 95% CI | Odds ratio M-H, fixed, 95% CI |
|------------------|-------------------|-------------------|--------|-------------------------------|-------------------------------|
| Yenice et al., 2006 | 3 | 40 | 3 | 40 | 0.8% | 1 [0.19, 5.28] |
| Di Bisceglie et al., 2007 | 18 | 189 | 27 | 191 | 6.8% | 0.64 [0.34, 1.2] |
| McHutchison et al., 2009 | 414 | 1035 | 479 | 1019 | 80.8% | 0.75 [0.63, 0.9] |
| Ascione et al., 2010 | 18 | 212 | 23 | 224 | 5.7% | 0.81 [0.42, 1.55] |
| Rumi et al., 2010 | 4 | 160 | 22 | 160 | 6% | 0.16 [0.05, 0.48] |
| **Total (95% CI)** | **1636** | **1634** | **100%** | **0.71 [0.61, 0.84]** |  |

Total events 457 554

Heterogeneity: $\chi^2 = 7.94, df = 4 (P = 0.09); I^2 = 50$

Test for overall effect: $Z = 4.14 (P < 0.0001)$

- **(b) The discontinuation rate of naïve CHC patients treated with the two types of peginterferons**

| Study or subgroup | Peginterferon α-2a | Peginterferon α-2b | Weight | Odds ratio M-H, fixed, 95% CI | Odds ratio M-H, fixed, 95% CI |
|------------------|-------------------|-------------------|--------|-------------------------------|-------------------------------|
| Scotto et al., 2008 | 6 | 71 | 3 | 72 | 1.3% | 2.12 [0.51, 8.84] |
| McHutchison et al., 2009 | 264 | 1035 | 254 | 1019 | 92.7% | 1.03 [0.85, 1.26] |
| Rumi et al., 2010 | 22 | 212 | 14 | 219 | 6% | 1.7 [0.84, 3.41] |
| **Total (95% CI)** | **1318** | **1310** | **100%** | **1.09 [0.9, 1.31]** |  |

Total events 292 271

Heterogeneity: $\chi^2 = 2.67, df = 2 (P = 0.26); I^2 = 25$

Test for overall effect: $Z = 0.85 (P = 0.4)$

- **(c) Peginterferon dose modification of CHC patients treated with the two types of peginterferons**

| Study or subgroup | Peginterferon α-2a | Peginterferon α-2b | Weight | Odds ratio M-H, fixed, 95% CI | Odds ratio M-H, fixed, 95% CI |
|------------------|-------------------|-------------------|--------|-------------------------------|-------------------------------|
| Yenice et al., 2006 | 1 | 40 | 2 | 40 | 0.7% | 0.49 [0.04, 5.6] |
| Scotto et al., 2008 | 5 | 71 | 3 | 72 | 0.9% | 1.74 [0.4, 7.58] |
| McHutchison et al., 2009 | 322 | 1035 | 338 | 1019 | 80.2% | 0.91 [0.76, 1.1] |
| Rumi et al., 2010 | 119 | 212 | 123 | 219 | 18.1% | 1 [0.68, 1.46] |
| **Total (95% CI)** | **1358** | **1350** | **100%** | **0.93 [0.79, 1.1]** |  |

Total events 447 466

Heterogeneity: $\chi^2 = 1.16, df = 3 (P = 0.76); I^2 = 0$

Test for overall effect: $Z = 0.85 (P = 0.4)$

- **(d) Ribavirin dose modification of CHC patients treated with the two types of peginterferons**

**Figure 4:** The discontinuation rates and drugs modification of CHC patients who received the two regimens.
difference between the two groups (32.9% versus 34.5%, OR = 0.93, 95% CI = 0.79–1.10, and P = 0.40; Figure 4(d)).

3.5. Relapse Rate. No difference in relapse rate for CHC patients treated with the two regimens was noted in the meta-analysis of RCTs [5, 7–11] by a fixed-effects model (28.1% versus 24.2%, OR = 1.23, 95% CI = 1.00–1.51, and P = 0.05; Figure 5(a)). However, subgroup analysis showed that, for naïve CHC patients, peginterferon α-2a obtained a higher relapse rate than peginterferon α-2b (28.3% versus 24.0%, OR = 1.25, 95% CI = 1.02–1.54, and P = 0.03; Figure 5(b)). For HCV genotype 1 patients, peginterferon α-2a had a higher relapse rate than peginterferon α-2b (32.9% versus 26.7%, OR = 1.35, 95% CI = 1.07–1.70, and P = 0.01; Figure 5(c)).

4. Discussion

Most previous meta-analyses concluded that peginterferon α-2a has higher SVR rate than peginterferon α-2b in CHC patients, but no difference in the safety profile was noted [12–15]. However, a recent meta-analysis has revealed that these two types of peginterferons have similar effects on RVR, SVR, and tolerability [29]. Moreover, the above analyses included either meeting abstracts or coinfected patients of HIV/HCV,
which may have an impact on the conclusions. In the present meta-analysis, we included more RCTs and restricted our trial analyses to full papers. We excluded abstracts because they did not contain adequate details of patients and outcomes.

Interferon-based therapy could lower the risk of cirrhosis and hepatocellular carcinoma and improve the survival of CHC patients who have an SVR with a large possibility through eradicating HCV and cutting liver fibrosis processes. Our analysis showed that peginterferon α-2a might achieve a higher SVR rate than peginterferon α-2b, including nonresponders. Subgroup analysis revealed that peginterferon α-2a was also more effective than peginterferon α-2b for HCV genotype 1 or 4 patients or treatment-naïve patients. However, these two types of peginterferons had similar SVR effects on HCV genotype 2 or 3 patients. These analyses indicated a difference in antiviral activity between the two therapeutic regimens. A previous study [30] proved that combination therapy with peginterferon α-2a is an independent pretreatment predictor of SVR (OR = 1.88, 95% CI = 1.20–2.96). Peginterferon α-2a achieves higher SVR rates than peginterferon α-2b in patients infected with HCV-1 and HCV-2; however, the two therapeutic regimens obtain similar SVR rates in patients infected with HCV-3 and HCV-4 [9]. Our results indicated that patients with genotype 2 or 3 had similar SVR rates in both groups. Given that the patients included in this meta-analysis mostly had HCV genotype 1 or 4, only less than 200 patients in each group were infected with HCV genotype 2 or 3; high-quality trials with a large sample size are needed to estimate the efficacy of the two regimens for genotype 2 or 3 CHC patients, especially for the comparison of the therapeutic efficacy in each genotype stratum.

Further analysis showed that no significant difference in RVR rate was found in the patients treated with the two peginterferon-α-based regimens. However, peginterferon α-2a could achieve higher EVR and ETR rates in CHC patients than peginterferon α-2b. Early eradication of HCV is important to the therapeutic resolution of CHC, and RVR remains the most notable on-treatment response predictor of SVR. Moreover, the present guidelines concluded that the absence of EVR is the most robust means of identifying nonresponders. Approximately 97%–100% of the treatment-naïve patients with HCV genotype 1 infection who did not reach EVR failed to elicit SVR. Thus, patients without EVR can discontinue therapy early without compromising their chance to elicit SVR [1, 2]. This finding might be associated with the potentially higher SVR rate of patients treated with peginterferon α-2a. ETR does not accurately predict the occurrence of SVR; however, ETR is necessary for SVR to take place [1, 2, 31].

Our meta-analysis of RCTs [5–10] suggests that the two peginterferons may be comparable with regard to any reasons leading to treatment discontinuation, including naïve and retreatment patients with any HCV genotype. However, for naïve CHC patients, peginterferon α-2a had a significantly lower discontinuation rate than peginterferon α-2b. Previous meta-analyses [12–15] concluded that peginterferon α-2a has a similar safety profile as peginterferon α-2b. Given that our results were based on ITT analysis, all patients who withdrew therapy were considered as treatment discontinuation, either for adverse events or nonsafety reasons. The reason above may explain why our analysis of discontinuation rate in naïve CHC patients conflicted with those of the previous studies.

Although peginterferon α-2a should achieve higher virologic responses and gain lower discontinuation rate, peginterferon α-2a had a higher relapse rate than peginterferon α-2b. The high relapse rate with peginterferon α-2a was a novelty, as in previous studies. Relapse rates ranged from 17% to 25% for peginterferon α-2a in patients with HCV genotype 1 [32, 33], which is significantly lower than the 31.5% reported in the IDEAL study [8]. These findings were not supported by two randomized studies that reported no difference in relapse rate between the two regimens [9, 10]. Many factors might have contributed to the difference in the findings above. Some of these factors include differences in epidemiological and genetic characteristics, mean body weight, distribution of genotype CC in the IL28B polymorphism, and ribavirin dose reduction schemes applied to the two regimens [34]. Maintaining a high ribavirin dose (≥12 mg/kg/day) during the full treatment period can lead to suppression of relapse in HCV-1 patients responding to peginterferon α-2b plus ribavirin. Ribavirin dosing seems to be instrumental in preventing posttreatment relapse [35], and ribavirin concentration in the later stages of treatment is an important marker for discriminating relapse [34, 36]. In the present meta-analysis, no significant difference in peginterferon and/or ribavirin dose reduction was found between the two groups. However, in the IDEAL study by McHutchison et al. [8], the dose reduction for the peginterferon α-2b arm occurred in two steps. The first step was a reduction of either 200 mg (in patients receiving 800 mg/day–1,200 mg/day of ribavirin) or 400 mg (in patients receiving 1,400 mg/day). The second step was reduction by another 200 mg, if required for resolution of the adverse event. For the peginterferon α-2a arm, the dose was reduced to 600 mg/day. The abrupt reduction of ribavirin dose to 600 mg/day might have played a crucial role in the high relapse rates observed in patients receiving the peginterferon α-2a regimen [8–10, 34].

Therefore, the peginterferon α-2a regimen holds a slight advantage in terms of virologic responses and discontinuation rates compared with the peginterferon α-2b regimen. This advantage may be considered as a direct consequence of the better pharmacokinetic profile of peginterferon α-2a than peginterferon α-2b. The pharmacodynamic properties of peginterferon α-2a allow slower absorption and elimination than peginterferon α-2b. Therefore, maximum concentrations occur later with peginterferon α-2a than with peginterferon α-2b. Peginterferon α-2b is associated with fluctuating blood levels and rapid rise and fall in the blood level because of the relatively rapid release of interferon α-2b molecule [37–39]. Previous studies [38, 40] showed that the concentration of peginterferon α-2b did not remain stable over the week as a whole. At the end of the week, serum interferon could not be detected in most patients treated with peginterferon α-2b. When interferon was no longer detectable in the serum, the viral load increased until the next interferon injection. This phenomenon increases the potential for more side effects and reduces the efficacy of the
drug. Peginterferon α-2b is distributed widely in the body fluids and tissues [14, 39]. By contrast, peginterferon α-2a is distributed predominantly to the blood and interstitial fluid, resulting in high drug concentrations in the liver. The reduced clearance of peginterferon α-2a, as a consequence of metabolism via nonspecific proteases, provides significant, consistent, and measurable therapeutic plasma levels even at the end of the weekly dosing period [41]. These differences between the two types of peginterferons should lead to better compliance and superior safety of peginterferon α-2a [14].

In conclusion, current evidence suggests that peginterferon α-2a has superior efficacy with higher EVR, ETR, and SVR than peginterferon α-2b for CHC patients, both plus ribavirin. Peginterferon α-2a might obtain similar or even lower discontinuation rate than peginterferon α-2b. However, peginterferon α-2a had a higher relapse rate than peginterferon α-2b. Further trials must focus on the comparison of the two types of peginterferons in terms of achieving SVR and clinically relevant outcomes, such as liver-related cirrhosis, hepatocellular carcinoma, mortality, and morbidity.

**Abbreviations**

CHC: Chronic hepatitis C  
HCV: Hepatitis C virus  
RVR: Rapid virologic response  
EVR: Early virologic response  
ETR: End-of-treatment virologic response  
SVR: Sustained virologic response  
CI: Confidence interval.

**Conflict of Interests**

The authors declare that they have no conflict of interests.

**Acknowledgments**

This work was supported mainly by the Shanghai Science and Technology Commission Project (no. 25382), the Shanghai Municipal Health Bureau (20114y020), and the Fundamental Research Funds for the Central Universities (no. 10F115).

**References**

[1] M. Omata, T. Kanda, M. L. Yu et al., “APASL consensus statements and management algorithms for hepatitis C virus infection,” *Hepatology International*, vol. 6, pp. 409–435, 2012.

[2] European Association for the Study of the Liver, "EASL clinical practice guidelines: management of hepatitis C virus infection," *Journal of Hepatology*, vol. 55, no. 2, pp. 245–264, 2011.

[3] L. B. Seeff, “The history of the “natural history” of hepatitis C (1968–2009),” *Liver International*, vol. 29, supplement 1, pp. 89–99, 2009.

[4] E. A. K. Schaefer and R. T. Chung, “Anti-hepatitis C virus drugs in development,” *Gastroenterology*, vol. 142, pp. 1340–1350, 2012.

[5] N. Yenice, O. Mehtap, M. Gümrah, and N. Arican, “The efficacy of pegylated interferon alpha 2a or 2b plus ribavirin in chronic hepatitis C patients,” *Turkish Journal of Gastroenterology*, vol. 17, no. 2, pp. 94–98, 2006.

[6] A. M. Di Bisceglie, R. H. Ghalib, F. M. Hamzeh, and V. K. Rustgi, “Early virologic response after peginterferon alpha-2a plus ribavirin or peginterferon alpha-2b plus ribavirin treatment in patients with chronic hepatitis C,” *Journal of Viral Hepatitis*, vol. 14, no. 10, pp. 721–729, 2007.

[7] G. Scotto, V. Fazio, C. Fornabaio et al., “Peg-Interferon alpha-2a versus Peg-Interferon alpha-2b in nonresponders with HCV active chronic hepatitis: a pilot study,” *Journal of Interferon and Cytokine Research*, vol. 28, no. 10, pp. 623–630, 2008.

[8] J. G. McHutchison, E. J. Lawitz, M. L. Shiffman et al., “Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection,” *The New England Journal of Medicine*, vol. 361, no. 6, pp. 580–593, 2009.

[9] M. G. Rumi, A. Aghemo, G. M. Prati et al., “Randomized study of peginterferon-α2a plus ribavirin vs peginterferon-α2b plus ribavirin in chronic hepatitis C,” *Gastroenterology*, vol. 138, no. 1, pp. 108–115, 2010.

[10] A. Ascione, M. De Luca, M. T. Tartaglione et al., “Peginterferon alfa-2a plus ribavirin is more effective than peginterferon alfa-2b plus ribavirin for treating chronic hepatitis C virus infection,” *Gastroenterology*, vol. 138, no. 1, pp. 116–122, 2010.

[11] T. H. Mach, A. Ciesla, W. Warunek et al., “Efficacy of pegylated interferon alfa-2a or alfa-2b in combination with ribavirin in the treatment of chronic hepatitis caused by hepatitis C virus genotype 1b,” *Polskie Archiwum Medycyny Wewnetrzej*, vol. 121, no. 12, pp. 434–439, 2011.

[12] S. H. Zhao, E. Q. Liu, P. Chen et al., “A comparison of peginterferon α-2a and α-2b for treatment-naive patients with chronic hepatitis C virus: a meta-analysis of randomized trials,” *Clinical Therapeutics*, vol. 32, pp. 1565–1577, 2010.

[13] T. Awad, K. Thorlund, G. Hauser, D. Stimac, M. Mabrouk, and C. Glund, “Peginterferon alpha-2a is associated with higher sustained virological response than peginterferon alfa-2B in chronic hepatitis C: systematic review of randomized trials,” *Hepatology*, vol. 51, no. 4, pp. 1176–1184, 2010.

[14] A. K. Singal, S. C. Jampana, and B. S. Anand, “Peginterferon alfa-2a is superior to peginterferon alfa-2b in the treatment of naive patients with hepatitis C virus infection: meta-analysis of randomized controlled trials,” *Digestive Diseases and Sciences*, vol. 56, no. 8, pp. 2221–2226, 2011.

[15] S. M. Alavian, B. Behnava, and S. V. Tabatabaei, “The comparative efficacy and safety of peginterferon Alpha-2a vs. 2b for the treatment of chronic HCV infection: a meta-analysis,” *Hepatitis Monthly*, vol. 10, no. 2, pp. 121–131, 2010.

[16] J. P. T. Higgins and S. Green, Eds., *Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0*, The Cochrane Collaboration, 2011, http://handbook.cochrane.org/.

[17] J. P. T. Higgins and S. G. Thompson, “Quantifying heterogeneity in a meta-analysis,” *Statistics in Medicine*, vol. 21, no. 11, pp. 1539–1558, 2002.

[18] H. Berak, A. Horban, M. Wasilewski et al., “Randomized, open label trial comparing efficacy and safety of pegylated interferon alfa 2a vs alfa 2b treatment of patients with chronic hepatitis C infected with non 2/3 genotypes—12 Week virological response analysis,” *Hepatology*, vol. 42, p. 684A, 2005.

[19] A. Kolakowska-Rzadzko, H. Berok, M. Wasilewski, and A. Horbon, “Relevance between fibrosis and response to treatment with peginterferon alfa 2a vs alfa 2b with ribavirin in chronic hepatitis C genotype 3 patients. Randomized open label study,” *Hepatology*, vol. 48, p. A878, 2008.

[20] S. Sinha, P. Gulur, V. Patel, G. Hage-Nassar, and S. Tenner, “A randomized prospective clinical trial comparing pegylated...
interferon alpha 2a/ribavirin versus pegylated interferon alpha 2b/ribavirin in the treatment of chronic hepatitis C,” *The American Journal of Gastroenterology*, vol. 99, supplement, pp. S77–S78, 2004.

[21] A. Q. Khan, A. Awan, S. Shahbuddin, and Q. Igbal, “Peginterferon alfa 2a/ribavirin versus peginterferon alfa 2b/ribavirin combination therapy in chronic hepatitis C genotype 3,” *Gastroenterology*, vol. 132, p. A200, 2007.

[22] S. Kamal, D. Ghoraba, L. Nabegh et al., “Pegylated interferon alfa-2A vs. pegylated interferon alfa-2B, plus ribavirin for chronic hepatitis C genotype 4 patients: a randomized controlled trial,” *Hepatology*, vol. 50, pp. A1025–A1026, 2009.

[23] C. Magni, F. Niero, B. Argenteri et al., “Antiviral activity and tolerability between pegylated interferon alpha 2a and alpha 2b in naive patients with chronic hepatitis C: results of a prospective monocentric randomized trial,” *Hepatology*, vol. 50, p. A720, 2009.

[24] M. Silva, J. Poo, F. Wagner et al., “A randomised trial to compare the pharmacokinetic, pharmacodynamic, and antiviral effects of peginterferon alfa-2b and peginterferon alfa-2a in patients with chronic hepatitis C (COMPARE),” *Journal of Hepatology*, vol. 45, no. 2, pp. 204–213, 2006.

[25] S. Lee, I. H. Kim, S. H. Kim et al., “Efficacy and tolerability of pegylated interferon-α2a plus ribavirin versus pegylated interferon-α2b plus ribavirin in treatment-naive chronic hepatitis C patients,” *Intervirology*, vol. 53, no. 3, pp. 146–153, 2010.

[26] R. Bruno, P. Sacchi, V. Ciappina et al., “Viral dynamics and pharmacokinetics of peginterferon alpha-2a and peginterferon alpha-2b in naive patients with chronic hepatitis C: a randomized, controlled study,” *Antiviral Therapy*, vol. 9, no. 4, pp. 491–497, 2004.

[27] M. Laguno, C. Cifuentes, J. Murillas et al., “Randomized trial comparing pegylated interferon -2b versus pegylated interferon -2a, both plus ribavirin, to treat chronic hepatitis C in human immunodeficiency virus patients,” *Hepatology*, vol. 49, no. 1, pp. 22–31, 2009.

[28] G. Scotto, V. Fazio, C. Fornabai et al., “Early and sustained virological response in non-responders with chronic hepatitis C: a randomized open-label study of pegylated interferon-α-2a versus pegylated interferon-α-2b,” *Drugs*, vol. 68, no. 6, pp. 791–801, 2008.

[29] N. Coppola, M. Pisaturo, C. Sagnelli et al., “Efficacy and tolerability peginterferon α-2a and α-2b in patients with chronic hepatitis C by genotype 1: a meta-analysis,” *Digestive and Liver Diseases*, vol. 43, supplement, p. S94, 2011.

[30] A. Kau, J. Vermehren, and C. Sarrazin, “Treatment predictors of a sustained virologic response in hepatitis B and C,” *Journal of Hepatology*, vol. 49, no. 4, pp. 634–651, 2008.

[31] M. G. Ghany, D. B. Strader, D. L. Thomas, and L. B. Seeff, “Diagnosis, management, and treatment of hepatitis C: an update,” *Hepatology*, vol. 49, no. 4, pp. 1335–1374, 2009.

[32] M. W. Fried, M. L. Shiffman, K. R. Reddy et al., “Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection,” *The New England Journal of Medicine*, vol. 347, no. 13, pp. 975–982, 2002.

[33] S. J. Hadziyannis, H. Sette Jr., T. R. Morgan et al., “Peginterferon-α2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose,” *Annals of Internal Medicine*, vol. 140, no. 5, pp. 346–167, 2004.

[34] M. Rumi, A. Aghemo, and G. M. Prati, “Comparative trials of peginterferon α-2a and peginterferon α-2b for chronic hepatitis C,” *Journal of Viral Hepatitis*, vol. 19, supplement 1, pp. S7–S10, 2012.

[35] N. Hiramatsu, T. Oze, T. Yakushijin et al., “Ribavirin dose reduction raises relapse rate dose-dependently in genotype 1 patients with hepatitis C responding to pegylated interferon alpha-2b plus ribavirin,” *Journal of Viral Hepatitis*, vol. 16, no. 8, pp. 586–594, 2009.

[36] N. Furusyo, M. Murata, E. Ogawa et al., “Ribavirin concentration in the later stages of 48 week pegylated interferon-α2b plus ribavirin therapy for chronic hepatitis C is useful for predicting virological response,” *Journal of Antimicrobial Chemotherapy*, vol. 66, no. 5, pp. 1127–1139, 2011.

[37] S. Zeuzem, C. Welsch, and E. Herrmann, “Pharmacokinetics of peginterferons,” *Seminars in Liver Disease*, vol. 23, no. 1, pp. 23–28, 2003.

[38] R. Bruno, P. Sacchi, C. Scagnolari et al., “Pharmacodynamics of peginterferon alfa-2a and peginterferon alfa-2b in interferon-naïve patients with chronic hepatitis C: a randomized, controlled study,” *Alimentary Pharmacology and Therapeutics*, vol. 26, no. 3, pp. 369–376, 2007.

[39] G. R. Foster, “Pegylated interferons for the treatment of chronic hepatitis C: pharmacological and clinical differences between peginterferon-α-2a and peginterferon-α-2b,” *Drugs*, vol. 70, no. 2, pp. 147–165, 2010.

[40] C. Francois, V. Descamps, E. Brochot et al., “Relationship between the hepatitis C viral load and the serum interferon concentration during the first week of peginterferon-alpha-2b-ribavirin combination therapy,” *Journal of Medical Virology*, vol. 82, no. 10, pp. 1640–1646, 2010.

[41] G. R. Foster, “Review article: pegylated interferons: chemical and clinical differences,” *Alimentary Pharmacology and Therapeutics*, vol. 20, no. 8, pp. 825–830, 2004.